L-4F, an Apolipoprotein A-1 Mimetic, Dramatically Improves Vasodilation in Hypercholesterolemia and Sickle Cell Disease

Background—Hypercholesterolemia and sickle cell disease (SCD) impair endothelium-dependent vasodilation by dissimilar mechanisms. Hypercholesterolemia impairs vasodilation by a low-density lipoprotein (LDL)–dependent mechanism. SCD has been characterized as a chronic state of inflammation in which xanthine oxidase (XO) from ischemic tissues increases vascular superoxide anion (O2·−) generation. Recent reports indicate that apolipoprotein (apo) A-1 mimetics inhibit atherosclerosis in LDL receptor–null (Ldlr−/−) mice fed Western diets. Here we hypothesize that L-4F, an apoA-1 mimetic, preserves vasodilation in hypercholesterolemia and SCD by decreasing mechanisms that increase O2·− generation. Methods and Results—Arterioles were isolated from hypercholesterolemic Ldlr−/− mice and from SCD mice that were treated with either saline or L-4F (1 mg/kg per day). Vasodilation in response to acetylcholine was determined by videomicroscopy. Effects of L-4F on LDL-induced increases in endothelium-dependent O2·− generation were determined on arterial segments via the hydroethidine assay and on stimulated endothelial cell cultures via superoxide dismutase–inhibitable ferricytochrome c reduction. Effects of L-4F on XO bound to pulmonary arterioles and content in livers of SCD mice were determined by immunofluorescence. Hypercholesterolemia impaired vasodilation in Ldlr−/− mice, which L-4F dramatically improved. L-4F inhibited LDL-induced increases in O2·− in arterial segments and in stimulated cultures. SCD impaired vasodilation, increased XO bound to pulmonary endothelium, and decreased liver XO content. L-4F dramatically improved vasodilation, decreased XO bound to pulmonary endothelium, and increased liver XO content compared with levels in untreated SCD mice. Conclusions—These data show that L-4F protects endothelium-dependent vasodilation in hypercholesterolemia and SCD. Our findings suggest that L-4F restores vascular endothelial function in diverse models of disease and may be applicable to treating a variety of vascular diseases.

[1]  K. Pritchard,et al.  L-4F, an Apolipoprotein A-1 Mimetic, Restores Nitric Oxide and Superoxide Anion Balance in Low-Density Lipoprotein-Treated Endothelial Cells , 2003, Circulation.

[2]  K. Pritchard,et al.  Angiostatin: A Negative Regulator of Endothelial-Dependent Vasodilation , 2003, Circulation.

[3]  M. Fishbein,et al.  Influenza Infection Promotes Macrophage Traffic Into Arteries of Mice That Is Prevented by D-4F, an Apolipoprotein A-I Mimetic Peptide , 2002, Circulation.

[4]  M. Navab,et al.  Oxidized lipids as mediators of coronary heart disease , 2002, Current opinion in lipidology.

[5]  K. Pritchard,et al.  Native LDL and minimally oxidized LDL differentially regulate superoxide anion in vascular endothelium in situ. , 2002, American journal of physiology. Heart and circulatory physiology.

[6]  K. Pritchard,et al.  Native low-density lipoprotein induces endothelial nitric oxide synthase dysfunction: role of heat shock protein 90 and caveolin-1. , 2002, Free radical biology & medicine.

[7]  F. Ruschitzka,et al.  High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men , 2002, Circulation.

[8]  R. Lallone,et al.  Oral Administration of an Apo A-I Mimetic Peptide Synthesized From D-Amino Acids Dramatically Reduces Atherosclerosis in Mice Independent of Plasma Cholesterol , 2002, Circulation.

[9]  M. Gladwin,et al.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease , 2002, Nature Medicine.

[10]  M. Gladwin,et al.  Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  E. Fisher,et al.  Elevating High-Density Lipoprotein Cholesterol in Apolipoprotein E—Deficient Mice Remodels Advanced Atherosclerotic Lesions by Decreasing Macrophage and Increasing Smooth Muscle Cell Content , 2001, Circulation.

[12]  S. Kaul,et al.  Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part II , 2001, Circulation.

[13]  Jan Nilsson,et al.  Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I , 2001, Circulation.

[14]  S. Kaul,et al.  High-Dose Recombinant Apolipoprotein A-IMilano Mobilizes Tissue Cholesterol and Rapidly Reduces Plaque Lipid and Macrophage Content in Apolipoprotein E-Deficient Mice: Potential Implications for Acute Plaque Stabilization , 2001, Circulation.

[15]  D. Shih,et al.  HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[16]  G. Anantharamaiah,et al.  A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. , 2001, Journal of lipid research.

[17]  Leslie A. Smith,et al.  Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

[18]  R. Hebbel,et al.  Amendment history : Erratum ( September 2000 ) Hypoxia / reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice , 2018 .

[19]  E. Ellis,et al.  Augmented vasoconstriction and thromboxane formation by 15-F(2t)-isoprostane (8-iso-prostaglandin F(2alpha)) in immature pig periventricular brain microvessels. , 2000, Stroke.

[20]  J. Berliner,et al.  Structural Identification of a Novel Pro-inflammatory Epoxyisoprostane Phospholipid in Mildly Oxidized Low Density Lipoprotein* , 1999, The Journal of Biological Chemistry.

[21]  E. Rubin,et al.  Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. , 1997, Science.

[22]  M. Nieminen,et al.  Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. , 1997, Circulation.

[23]  H. Bunn Pathogenesis and treatment of sickle cell disease. , 1997, The New England journal of medicine.

[24]  J. Cooke,et al.  Arginine Restores Cholinergic Relaxation of Hypercholesterolemic Rabbit Thoracic Aorta , 1991, Circulation.

[25]  K. Zitnay,et al.  Loss of Selective Endothelial Cell Vasoactive Functions Caused by Hypercholesterolemia in Pig Coronary Arteries , 1988, Circulation research.

[26]  K. Bruckdorfer,et al.  Low-density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta , 1987, Nature.